Menopause Hormone Therapy: A Plain-English Guide to the Options

Why does "hormone therapy" mean five different decisions, not one?

Because the phrase gets used as if it's a single product, and it isn't. Every actual prescription involves separate choices that change the risk-benefit picture: which hormone (estrogen alone, or estrogen plus a progestogen), how it's delivered into your body (orally, through the skin, or locally), and when in your menopause transition you start.

Getting a plain answer to "should I do hormone therapy" is hard precisely because the honest answer depends on which version of hormone therapy is actually being discussed.

Do I need estrogen alone, or estrogen plus a progestogen?

This comes down to one anatomical fact: do you still have a uterus?

If you've had a hysterectomy, estrogen-only therapy (ET) is generally appropriate. Estrogen taken alone can be used for around 7 years before breast cancer risk meaningfully increases, according to patient guidance from the Menopause Society.

If you still have a uterus, you need estrogen combined with a progestogen (EPT). The progestogen isn't optional decoration, it protects the uterine lining from the cancer risk that unopposed estrogen would otherwise raise. The tradeoff: breast cancer risk with combined therapy starts rising sooner, generally after 3 to 5 years of use, compared to roughly 7 years with estrogen alone.

This is exactly the kind of decision that needs a real conversation with a prescriber who knows your history, not a generic recommendation.

Does it matter whether I take a pill versus a patch?

Yes, and this is one of the most underdiscussed parts of the decision. It's not just about convenience or preference.

Current guidance, including the UK's NICE 2024 recommendations, is fairly direct: blood clot (venous thromboembolism, or VTE) risk is not meaningfully increased with transdermal hormone therapy (patches, gels, sprays), while oral pills do carry an increased VTE risk. This matters more for some people than others: NICE specifically recommends considering transdermal delivery over oral for anyone with elevated clot risk factors, including a BMI above 30.

The reason has to do with how the liver processes the hormone. Oral estrogen passes through the liver first, which affects clotting factors in a way transdermal delivery mostly avoids. If you're being prescribed a pill without any discussion of this tradeoff, that's a reasonable thing to ask about directly.

What's the difference between systemic and local (vaginal) therapy?

This distinction trips people up because both involve "hormone therapy," but they're solving different problems with very different risk exposure.

Systemic therapy, whether pill, patch, gel, or spray, distributes hormone throughout your bloodstream and is what treats body-wide symptoms: hot flashes, night sweats, sleep disruption tied to those symptoms.

Local (vaginal) therapy, delivered as a low-dose ring, cream, or tablet placed directly in the vagina, targets genitourinary symptoms specifically, vaginal dryness, thinning tissue, discomfort, with minimal absorption into the rest of the body. Because the systemic exposure is so low, the risk profile is meaningfully different from systemic therapy, which is why some people who aren't candidates for (or don't want) systemic hormone therapy can still reasonably use local vaginal estrogen for genitourinary symptoms specifically.

Conflating these two, treating a low-dose vaginal prescription as if it carries the same considerations as a systemic pill, is a common source of unnecessary worry.

Does timing actually change the risk-benefit calculation?

Yes, meaningfully. This is often called the "window of opportunity" in the clinical literature. The benefit-risk balance for hormone therapy is generally most favorable when it's started within 10 years of your last period or before age 60. Starting well outside that window changes the calculation, which is part of why this isn't a decision to make in isolation from your actual menopause timeline.

This timing consideration is also relevant to the FDA's 2026 decision to remove the black box warning that had been attached to hormone therapy since the early 2000s, largely based on the original Women's Health Initiative data. We've written about that FDA change directly — part of what changed is a better understanding that the original WHI data, drawn from an older population starting therapy well past the "window," doesn't generalize cleanly to someone starting therapy near menopause onset.

Is hormone therapy the only option?

No, and it's worth saying plainly: hormone therapy is one tool, not the whole toolkit. Non-hormonal medications exist for hot flashes, lifestyle factors (sleep, training, nutrition) genuinely move the needle on how the menopause transition feels, and some people are not good candidates for hormone therapy at all because of personal history (certain cancers, clotting disorders, active liver disease, among others).

The point of a real consultation is figuring out which category you're actually in, not defaulting to a single recommendation regardless of your history.

How does Vitality Dartmouth approach this conversation?

Educationally and honestly about scope. I'm a registered nurse: I build the surrounding program, coach the training and lifestyle side, and help you understand what your labs and symptoms are actually telling you. I don't prescribe hormone therapy or write the prescription for any specific product. Our collaborating NP or MD evaluates your history, discusses estrogen-alone versus combined therapy, delivery method, and timing with you directly, and writes every prescription and order.

What we bring to that conversation is context: your labs, your symptom pattern, and a program built around whatever decision you and your prescriber land on, whether that's hormone therapy, a non-hormonal approach, or some combination. Our genomic and lab testing and Genomic Menopausal Reset are often where that context gets built.

Does this look different on the SouthCoast?

The clinical decisions are the same everywhere. What's different locally is whether someone actually walks you through estrogen-alone versus combined, delivery method tradeoffs, and timing, instead of a five-minute conversation that ends in a single default prescription.

We work with women across Dartmouth, New Bedford, Westport, Fairhaven, and Fall River who've either been told hormone therapy is categorically off the table (often based on outdated blanket guidance) or handed a prescription with none of these distinctions explained.

Frequently asked questions

Ready to have this conversation with real context behind it?

If you're trying to figure out whether hormone therapy makes sense for you, or you've been given a prescription without any explanation of the choices behind it, book a free discovery call. We'll go through what's actually being decided and connect you with a prescriber who can walk through the options directly.

This article is general health education and is not medical advice, a diagnosis, or a treatment recommendation for any individual. It does not create a clinician-patient relationship. Vitality Dartmouth is an RN-led clinic; all prescriptions and diagnostic orders are written by a collaborating nurse practitioner or physician. Individual results, risks, and appropriate candidacy for hormone therapy vary and depend on personal and family medical history. No outcome is promised or guaranteed. Do not start, change, or stop any hormone therapy based on this article. Talk with your own licensed healthcare provider about your situation, and call 911 for a medical emergency.